HomeCompareGBS vs MAIN

GBS vs MAIN: Dividend Comparison 2026

GBS yields 422.65% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBS wins by $17122.36M in total portfolio value
10 years
GBS
GBS
● Live price
422.65%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17170.31M
Annual income
$11,716,925,996.02
Full GBS calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — GBS vs MAIN

📍 GBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGBSMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GBS + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GBS pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBS
Annual income on $10K today (after 15% tax)
$35,925.61/yr
After 10yr DRIP, annual income (after tax)
$9,959,387,096.62/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, GBS beats the other by $9,925,209,702.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBS + MAIN for your $10,000?

GBS: 50%MAIN: 50%
100% MAIN50/50100% GBS
Portfolio after 10yr
$8609.13M
Annual income
$5,878,567,347.57/yr
Blended yield
68.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

GBS
No analyst data
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBS buys
0
MAIN buys
0
No recent congressional trades found for GBS or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGBSMAIN
Forward yield422.65%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$17170.31M$47.95M
Annual income after 10y$11,716,925,996.02$40,208,699.11
Total dividends collected$16675.91M$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: GBS vs MAIN ($10,000, DRIP)

YearGBS PortfolioGBS Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$52,965$42,265.43$12,464$1,223.78+$40.5KGBS
2$265,889$209,215.55$16,353$2,343.58+$249.5KGBS
3$1,266,062$981,561.13$23,105$4,724.42+$1.24MGBS
4$5,722,749$4,368,062.66$36,226$10,256.23+$5.69MGBS
5$24,575,825$18,452,483.99$65,426$24,707.64+$24.51MGBS
6$100,354,560$74,058,426.77$142,101$68,562.02+$100.21MGBS
7$390,010,320$282,630,940.68$388,521$228,799.95+$389.62MGBS
8$1,443,848,768$1,026,537,725.78$1,397,868$961,169.80+$1442.45MGBS
9$5,096,622,021$3,551,703,839.84$6,884,663$5,313,459.69+$5089.74MGBS
10$17,170,311,559$11,716,925,996.02$47,947,060$40,208,699.11+$17122.36MGBS

GBS vs MAIN: Complete Analysis 2026

GBSStock

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Full GBS Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this GBS vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBS vs SCHDGBS vs JEPIGBS vs OGBS vs KOGBS vs ARCCGBS vs HTGCGBS vs GBDCGBS vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.